

Baptist Health South Florida

Scholarly Commons @ Baptist Health South Florida

All Publications

2021

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53

Guilherme Rabinowits

Baptist Health Medical Group; Miami Cancer Institute, guilhermer@baptisthealth.net

Follow this and additional works at: <https://scholarlycommons.baptisthealth.net/se-all-publications>

Citation

Clinical Cancer Research (2021) [Epub ahead of print] Published online: July 22

This Article -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type *TP53*

Mansoor N. Saleh,^{1 §} Manish R. Patel,² Todd M Bauer,³ Sanjay Goel,⁴ Gerald S. Falchook,⁵ Geoffrey I. Shapiro,⁶ Ki Y. Chung,⁷ Jeffrey R. Infante,^{3 †} Robert M. Conry,⁸ Guilherme Rabinowits,^{6 ‡} David S. Hong,⁹ Judy S. Wang,² Ulrich Steidl,⁴ Gurudatta Naik,¹ Vincent Guerlavais,¹⁰ Vojislav Vukovic,¹⁰ D. Allen Annis,¹⁰ Manuel Aivado,¹⁰ Funda Meric-Bernstam⁹

¹O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, USA

²Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida USA

³Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN USA

⁴Albert Einstein College of Medicine - Montefiore Medical Center, The Bronx, NY USA

⁵Sarah Cannon Research Institute at HealthONE, Denver, Colorado USA

⁶Dana-Farber Cancer Institute, 19 Worcester St, Boston, Massachusetts USA

⁷Prisma Health Cancer Institute, Greenville, South Carolina USA

⁸The Kirkland Clinic at Acton Road, Birmingham, Alabama USA

⁹The University of Texas MD Anderson Cancer Center, Houston, Texas USA

¹⁰Aileron Therapeutics, Inc., Watertown, Massachusetts USA

§ Present address: The Aga Khan University Hospital, Nairobi, Kenya

† Present address: Janssen Pharmaceuticals, Horsham, Pennsylvania 19044, USA

‡ Present address: Miami Cancer Institute, Miami, Florida USA

Corresponding authors:

Mansoor Saleh, MD

The Aga Khan University

3rd Parklands Avenue, Nairobi-Kenya

mansoor.saleh@aku.edu

Phone: +254 709 93 1500

Funda Meric-Bernstam, MD

The University of Texas MD Anderson Cancer Center

1400 Holcombe Blvd, Houston, TX, 77030

fmeric@mdanderson.org

Phone: 713-794-1226

Running Title: “Phase 1 Trial of ALRN-6924, a Dual MDMX/MDM2 Inhibitor”

Keywords: TP53, p53, Mouse double minute2 homolog, HDM2, MDM2

Funding: Aileron Therapeutics

List of where and when the study has been presented in part elsewhere, if applicable:

Presented in part at the 2017 annual meeting of the American Society of Clinical Oncology

Word Count: 5,444

Total Number of Figures and Tables: 3 Figures, 3 Tables

Authors' Disclosures:

MNS, MRP, FMB, US, SG and JSW have received research grants from Aileron Therapeutics to their respective institutions.

GSF has received Royalties (self) from Wolters Kluwer (2014-present), advisory role fees (to institution) from Fujifilm (2018), advisory role fees (self) from EMD Serono (2010, 2011), travel-related fees (self, for work or research related to institution) from Bristol-Myers Squibb (2015), EMD Serono (2011, 2012, 2013), Fujifilm (2018), Millennium (2013), Sarah Cannon Research Institute, speakers honorarium for CME from Total Health Conferencing (2019), Rocky Mountain Oncology Society (2020), and research funding [to institution, for any trial for which I have been the PI (ever) or subinvestigator (minimum last 4 years)] from 3-V Biosciences, Abbisko, Abbvie, ADC Therapeutics, Aileron, American Society of Clinical Oncology, Amgen, ARMO, AstraZeneca, BeiGene, Bioatla, Bioinvent, Biothera, Bicycle, Celldex, Celgene, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Epizyme, Exelixis, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Jounce, Kolltan, Loxo, MedImmune, Millennium, Merck, miRNA Therapeutics, National Institutes of Health, Novartis, OncoMed,

Oncorus, Oncothyreon, Poseida, Precision Oncology, Prelude, Regeneron, Rgenix, Ribon, Sapience, Strategia, Syndax, Synthorx, Taiho, Takeda, Tarveda, Tesaro, Tocagen, Turning Point Therapeutics, U.T. MD Anderson Cancer Center, Vegenics, Xencor.

DSH has received research/grant funding to his institution from AbbVie, Adaptimmune, Aldi-Norte, Amgen, Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, miRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Numab, Pfizer, Seattle Genetics, Takeda, Turning Point Therapeutics, Verstatem; travel, accommodations and/or expenses from Bayer, LOXO, miRNA, Genmab, AACR, ASCO, SITC; consulting or advisory role fees from Alpha Insights, Acuta, Amgen, Axiom, Adaptimmune, Baxter, Bayer, Boxer Capital, COG, ECOR1, Expert Connect, Genentech, GLG, Group H, Guidepoint, H.C. Wainwright, Infinity, Janssen, Merrimack, Medscape, NTRK Connect, Numab, Pfizer, Prime Oncology, Seattle Genetics, SlingShot, Takeda, Trieza Therapeutics, WebMD; other ownership interests include Molecular Match (Advisor), OncoResponse (Founder), Presagia Inc (Advisor). JSW has received research funding to her institution from ADC Therapeutics, Agenus, AstraZeneca, Bicycle, BioNTech, Birdie/7,8 Pharma, Black Diamond, Boehringer Ingelheim, Bristol-Myers/Squibb, Celgene, Chckpoint, Ciclomed, Clovis, Curis, CytomX, DaiichiSankyo, eFFECTOR, Eli Lilly, Evelo, Forma, Genentech/Roche, Gilead, GlaxoSmithKline, H3Bio, Hengrui, Hutchinson MediPharm, IGM, Ignyta, Incyte, Jacobio, Janssen, Jounce, Klus Pharma, Kyman, LoXO, LSK BioPartners, Lycera, MabVax, MabSpace, Macrogenics, Medimmune, Merck, Miati, Moderna, Novartis, Olema, ORIC, Pfizer, Phoenix Molecular Designs, Prelude, Relay, Revolution, Ribon, Puget Sound Biologics, Stemline, Syndax, Synthorx, Taiho, Takeda, Tesaro, TopAlliance, Traadwell, Vedanta, Verastern, Viegeo, Xencor; advisory board honoraria from BioNTech and speaker's bureau fees from AstraZeneca.

US has received consulting fees from Aileron Therapeutics, GlaxoSmithKline, Bayer Healthcare, Aileron Therapeutics, Novartis; compensation for consultancy services and for serving on scientific advisory boards from GlaxoSmithKline, Bayer Healthcare, Celgene, Aileron Therapeutics, Stelexis Therapeutics, Pieris Pharmaceuticals, and Vor Biopharma; has equity ownership in and is serving on the board of directors of Stelexis Therapeutics.

VV, VG, DAA, and MA are employees of, and have stock in, Aileron Therapeutics.

FMB has received research/grant funding to her institution from AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Millennium Pharmaceuticals Inc., Novartis, Puma Biotechnology Inc., Taiho Pharmaceutical Co.; Consulting fees from Aduro BioTech Inc., Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., Genentech Inc., IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tyra Biosciences, Xencor, Zymeworks; Advisory Committee fees from Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, Zentalis; Honoraria for speaking engagements from Chugai Biopharmaceuticals, Mayo Clinic, Rutgers Cancer Institute of New Jersey and travel-related fees from Beth Israel Deaconess Medical Center.

JRI, TMB, GIS, KC, RMC, GR and GN have no conflicts to declare.

Translational Relevance

The p53 tumor suppressor protein and its endogenous regulator MDM2 have been a focus of cancer research for over 30 years, with several small molecule inhibitors of MDM2 evaluated in clinical trials. However, no inhibitors of MDMX, the second regulator of p53, have been tested clinically, due in part to the challenge of developing small molecule inhibitors of the p53-MDMX interface. Stapled Peptides are a new therapeutic modality capable of disrupting protein-protein interactions in cells. ALRN-6924, a dual MDM2/MDMX inhibitor, is the first member of this new modality to reach the clinic. We evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor effects of ALRN-6924 in patients with solid tumors or lymphomas, and show that ALRN-6924 was well tolerated with encouraging anti-tumor activity, including durable complete and partial responses with more than half of evaluable patients achieving disease control. Strikingly, the hematopoietic toxicity typically observed for selective MDM2 inhibitors was nearly absent for ALRN-6924, suggesting that dual MDM2/MDMX inhibition may allow for more complete p53 activation with a toxicity profile that would allow for combination therapy and use as a chemoprotection agent.

PURPOSE

We describe the first-in-human dose-escalation trial for ALRN-6924, a stabilized, cell-permeating peptide that disrupts p53 inhibition by MDM2 and MDMX to induce cell cycle arrest or apoptosis in *TP53* wild-type tumors.

METHODS

Two schedules were evaluated for safety, pharmacokinetics, pharmacodynamics, and anti-tumor effects in patients with solid tumors or lymphomas: In arm A, patients received ALRN-6924 by intravenous infusion once-weekly for 3 weeks every 28 days; arm B, was twice-weekly for 2 weeks every 21 days.

RESULTS

Seventy-one patients were enrolled: 41 in arm A (0.16-4.4 mg/kg), 30 in arm B (0.32-2.7 mg/kg). ALRN-6924 showed dose-dependent pharmacokinetics and increased serum levels of MIC-1, a biomarker of p53 activation. The most frequent treatment-related adverse events were gastrointestinal side effects, fatigue, anemia, and headache. In arm A, at 4.4 mg/kg, dose-limiting toxicities (DLTs) were Grade 3 (G3) hypotension, G3 alkaline phosphatase elevation, G3 anemia, and G4 neutropenia in one patient each. At the maximum tolerated dose in arm A of 3.1 mg/kg, G3 fatigue was observed in one patient. No DLTs were observed in arm B. No G3/G4 thrombocytopenia was observed in any patient. Seven patients had infusion-related reactions; three discontinued treatment. In 41 efficacy-evaluable patients with *TP53* wild-type disease across both schedules the disease control rate was 59%. Two patients had confirmed complete responses, two had confirmed partial responses, 20 had stable disease. Six patients were treated for >1 year. The recommended phase 2 dose was schedule A, 3.1 mg/kg.

CONCLUSION

ALRN-6924 was well tolerated and demonstrated anti-tumor activity.

Introduction

Commonly referred to as “the guardian of the genome,” p53 plays a central role in the mechanisms that defend the human body from cancer.¹ The natural tumor suppressor function of p53 involves responding to DNA damage by arresting cell division, allowing for repair, and if repair is unsuccessful, inducing an apoptotic response. To subvert this anti-tumor functionality, cancer cells neutralize p53 by deletion, mutation, degradation, or sequestration.^{2,3} The latter two mechanisms are mediated by protein-protein interactions between p53 and its negative regulators mouse double minute 2 (MDM2), which binds and destroys p53; and MDMX, which binds and sequesters p53.^{4,5} Mutation of the *TP53* gene that encodes the p53 tumor suppressor protein has been observed in approximately 50% of adult and 4% of childhood cancers, highlighting the importance of p53 signaling.⁶ Conversely, many human cancers retain wild-type *TP53*, making reactivation of the natural p53 pathway by targeted inhibition of MDM2 and MDMX in *TP53* wild-type cancer cells an appealing strategy for therapeutic intervention.

MDM2 is an E3 ubiquitin-protein ligase that engages the transactivation domain of p53 by a helix-in-groove interaction.⁷ Whereas the MDM2-p53 interaction results in p53 ubiquitination and degradation, an analogous helix-in-groove interaction between MDMX and p53 thwarts transcriptional activity by complex formation. Although MDMX does not possess E3 ligase activity, it enhances MDM2-mediated degradation of p53.⁸ Importantly, both MDM2 and MDMX are essential to negative regulation and homeostasis of p53 at the organism level, as evidenced by the embryonic lethality of MDM2 or MDMX deletion in mice.^{9,10} In human cancer, the finding of suppression of p53 by overexpression of MDM2, whether by gene amplification or protein upregulation, inspired the development of small molecule MDM2 inhibitors to restore the p53 tumor suppressor pathway.¹¹ However, sequestration of drug-induced p53 by MDMX was found to be a mechanism of resistance to selective MDM2 inhibition.¹² While MDM2 inhibitors have now advanced to clinical

trials,¹³⁻¹⁵ clinically viable small molecules that target the corresponding groove on MDMX remain elusive. Given the hematopoietic toxicity—especially thrombocytopenia—observed upon selective MDM2 inhibition in the clinic¹⁶ and the role of MDMX in p53 suppression and in resistance to MDM2 inhibitor treatment, the development of dual MDM2- and MDMX-directed agents offers a path to more complete inhibition of negative p53 regulation. Yet, such agents have not been clinically tested.

Here, we report the results of the first phase 1 trial of ALRN-6924, a stabilized, cell-permeating α -helical peptide that mimics the transactivation domain α -helix of p53 to bind with high affinity to both MDMX and MDM2. ALRN-6924 represents a new class of inhibitors of intracellular protein-protein interactions, referred to as stapled peptides, that contain a bridging hydrocarbon linker to maintain the α -helical shape of bioactive peptides and simultaneously confer proteolytic resistance and cell permeability.¹⁷⁻¹⁹ While early stapled peptide prototypes showed inconsistent results *in vitro* under standard serum-containing tissue culture conditions,²⁰ detailed optimization of p53 stapled peptides to improve their biological and biophysical properties led to the development of ALRN-6924, which consistently demonstrated on-mechanism activity *in vitro* under standard serum-containing tissue culture conditions as well as anti-tumor activity in mouse models of *TP53* wild-type hematologic malignancies and solid tumors, providing proof-of-concept for clinical translation.²¹⁻²³ To evaluate the safety and preliminary activity of ALRN-6924 in human cancer, we conducted a phase 1 dose escalation study of 71 patients with advanced solid tumors or lymphomas. Now, we report the tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of this first-in-class representative of the novel stapled peptide therapeutic modality.

Methods

Patient Selection

Patients 18 years or older with advanced solid tumors or lymphomas were recruited to participate in this phase I, open-label, multicenter, dose escalation trial at eight centers throughout the United States. Patients with solid tumors were required to have at least one target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and patients with lymphomas were required to have at least one measurable lesion per Revised International Working Group Response Criteria (IWG) 2014, following the exhaustion of standard-of-care treatment options. Eligibility criteria also included Eastern Cooperative Oncology Group performance status of 0-1; life expectancy ≥ 3 months; and adequate hematologic, hepatic, coagulation, and renal function (see protocol in Supplemental Information for detailed eligibility criteria). Women with childbearing potential were required to have a negative serum or urine pregnancy test during screening. The shorter of 4 weeks or 5 half-lives was required for the washout of all prior therapeutic agents unless no drug-drug interaction was anticipated and the patient had unequivocally experienced disease progression during the most recent line of therapy.

Mandatory tumor *TP53* mutation status evaluation was conducted in fresh or archival (≤ 1 year old) tumor specimens using next-generation sequencing. However, for the three lowest dose levels of arm A, patients were enrolled irrespective of *TP53* mutation status. At higher dose levels, patients were required to have wild-type *TP53* based on either central or local laboratory assessment. Patients known to be human papillomavirus positive were also excluded from enrollment because viral E6 protein can mediate p53 degradation. Patients without archived tissue and for whom a biopsy posed a significant risk were not enrolled.

Based on low central nervous system penetration of ALRN-6924 prototypes observed in preclinical studies, patients with primary central nervous system tumors and patients with known brain metastasis were excluded unless these metastases had been treated and been clinically stable for at least 30 days. Patients with cardiovascular risk factors including the New York Heart Association class III or IV heart failure, uncontrolled arrhythmias or hypertension, and acute coronary syndromes within 6 months, as well as patients with active or uncontrolled infections, including HIV/AIDS and hepatitis B and C, were excluded. Any previous primary malignancy must have been in remission for at least 2 years, except for non-melanoma skin cancers, carcinomas in situ, or squamous intraepithelial neoplasms. Patients with pulmonary embolism, deep venous thrombosis, gastrointestinal hemorrhage in the past 6 months, hereditary angioedema of any severity, or history of severe or life-threatening angioedema due to any cause were also excluded. Lastly, use of concomitant medications that are predominantly cleared by organic anion transporter polypeptide (OATP) hepatobiliary transporters OATP1B1 and OATP1B3 was prohibited within 48 hours of ALRN-6924 infusion because ALRN-6924 is primarily cleared through hepatobiliary elimination and inhibits these transporters.

Before patient recruitment began at each participating site the protocol was approved by its institutional review board. All patients provided written informed consent before undergoing study-related procedures, including the molecular assessment of tumor specimens. This trial was conducted in accordance with current United States FDA regulations, ICH Good Clinical Practice Guidelines, the principles of the Declaration of Helsinki, and local ethical and legal requirements.. This trial is registered on ClinicalTrials.gov (NCT02264613).

Study Design and Treatment Plan

A standard 3+3 dose escalation design was employed to independently assess two single-agent dosing regimens: patients in treatment arm A received ALRN-6924 by intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle, while those in treatment arm B received ALRN-6924 on days 1, 4, 8, and 11 of a 21-day cycle. Enrollment began with arm A, and arm B was introduced once the third dose level on arm A was reached. Subsequently, patients were assigned to one of the two dosing regimens based on the availability of enrollment slots. Doses were doubled until ≥ 1 of 3 patients in a cohort experienced any grade ≥ 2 treatment-emergent adverse event (TEAE) that was possibly related to the study drug, at which time a modified Fibonacci sequence was implemented.²⁴ Intra-patient dose escalation was allowed.

The primary endpoints of the study were TEAEs, dose-limiting toxicities (DLTs), and safety assessments. Secondary endpoints included overall response rate, time to response, duration of response, disease control rate, and duration of clinical benefit. Pharmacologic secondary endpoints included pharmacokinetic parameters of ALRN-6924 and its primary metabolite; serum levels of macrophage inhibitory cytokine-1 (MIC-1), an established secreted biomarker of p53 activation; and immunogenicity as measured by anti-drug antibody levels in blood.

Treatment continued until unacceptable toxicity, disease progression, or patient or physician decision to end treatment. Patients experiencing clinical benefit could continue the study despite radiographic disease progression.

Toxicity Assessments

Adverse events were recorded at each visit and graded by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. DLTs were defined as any grade ≥ 3 non-hematologic adverse event, excluding the following: fatigue, nausea, emesis, diarrhea, or mucositis that responded to supportive treatment within 48 hours; electrolyte aberrations that responded to correction within 24 hours; and grade ≤ 3 infusion-related reactions that did not require hospitalization. Hematologic DLTs included grade 4 thrombocytopenia of any duration; grade 3 thrombocytopenia lasting ≥ 7 days or associated with clinically significant bleeding; grade 4 neutropenia lasting for ≥ 3 days; or any grade ≥ 3 febrile neutropenia.

Pharmacokinetics and Pharmacodynamics

The pharmacokinetic profiles of ALRN-6924 and its active metabolite ALRN-8714 in patient plasma were assessed using a validated liquid chromatography method with tandem mass spectrometric detection. Blood samples were obtained within 1 hour before the start and at the end of infusion (± 5 minutes) and at 0.5, 1, 2, 4, 8, 24, and 48 hours after infusion on cycle 1 day 1 in both arm A and arm B. In addition, selective sampling was done on subsequent dosing days in subsequent cycles of therapy in both regimens to evaluate accumulation of exposure, dose-to-dose variability, and changes in exposure due to possible induction or inhibition of clearance mechanisms. Pharmacokinetic parameters were calculated by non-compartmental analysis using Phoenix WinNonlin v.8.1 and included maximum plasma concentration (C_{max}), area under the plasma concentration curve (AUC), and half-life calculations.

The pharmacodynamic profile of MIC-1 was assessed in patient serum samples using a validated, quantitative sandwich enzyme-linked immunosorbent assay. Blood samples for serum MIC-1 levels were obtained in parallel with plasma pharmacokinetic samples at the collection times noted above.

Exploratory analyses included correlation of anti-tumor activity with baseline protein and gene expression levels of p53, MDM2, MDMX, and related biomarkers in tumor biopsy tissue. Fresh or archival (≤ 1 year old) formalin-fixed tumor specimens collected for next-generation sequencing of *TP53* were further used for immunohistochemistry analysis of protein biomarkers, and nucleic acid extracts for next-generation sequencing were further used for qRT-PCR analysis of gene expression levels (Supplementary Methods and Supplementary Table S1).

Response Assessment

Tumor response was assessed every 2 cycles (8 weeks) for patients in arm A and every 3 cycles (9 weeks) for patients in arm B. Response was determined by the investigators in accordance with RECIST 1.1 for patients with solid tumors²⁵ and IWG 2014 for lymphoma patients.²⁶ Patients were considered eligible for response assessment if they had received at least one dose of ALRN-6924 and had undergone post-baseline radiological tumor assessment or exhibited clinical or objective progression as determined by the investigator and excluded patients with *TP53*-mutant tumors and patients in the lowest dose levels (< 0.8 mg/kg). Data cutoff date for the response analysis was 10 May 2020.

Drug Supply and Administration

ALRN-6924 was supplied and stored in single-use glass vials as a refrigerated (2° to 8° C) liquid product dissolved at 15 mg/mL in 20 mM sodium phosphate, 240 mM trehalose, and 300 ppm polysorbate 20, pH 7.5. A weight-adjusted dose of the ALRN-6924 drug product was diluted into 250 mL, 5% dextrose in water for IV administration to patients via a 1-hour infusion, except for dose level 7-2 in arm A, which was infused over 2 hours.

Results

Patient Characteristics

From October 2014 to January 2017, 71 patients were enrolled, with 41 (58%) allocated to treatment arm A and 30 (42%) allocated to treatment arm B. At the time of data cutoff for analysis (13 April 2018), 66 (93.0%) of 71 patients had discontinued study treatment: 38 in treatment arm A and 28 in arm B. Key demographics and baseline characteristics are shown in Table 1 and were similar for those in treatment arms A and B. Overall, the median age was 61.0 years, and the percentages of men and women were similar (49.3% and 50.7%, respectively), and most patients were Caucasian (74.6%). The patient population was heavily pretreated, with 67.6% of patients having received more than two prior lines of systemic therapy, including 43.7% of patients with at least five lines of prior therapy. Though not an exclusion factor, no patients had prior therapy with an investigational MDM2 inhibitor. Of the 71 patients enrolled, 67 had solid tumors, and four patients had lymphomas. Patients in the study had 24 different tumor types; these included thymoma (n=5), peripheral T-cell lymphoma (PTCL; n=1), colorectal cancer (CRC; n=1), sarcoma (n=17), Merkel cell carcinoma (n=4), renal cell carcinoma (n=2), ovarian cancer (n=2), adenoid cystic carcinoma (n=5), hepatocellular carcinoma (n=1), melanoma (n=6), salivary gland cancer (n=3), breast cancer (n=3), and other cancers (n=21). Patients were enrolled irrespective of *TP53* status in the three lowest dose levels (n=12) of arm A, which preceded enrollment in arm B; therefore, the *TP53*-wild-type (WT) confirmation rate was higher for patients enrolled in arm B (100%) than in arm A (82.9%), or 90.1% (64/71) overall. Other patients had either mutant (n=2) or indeterminate (n=5) *TP53* status.

Patients were enrolled based on either central or local laboratory *TP53* assessment. Twenty-nine patients underwent both local and central laboratory testing, and five of these 29 patients (17.2%) had discrepant

results (all *TP53*-WT on local testing and *TP53*-mutant on central testing), possibly due to differences in gene coverage between local and central laboratory assays and instances in which different biopsy samples (from primary tumor or metastases) were analyzed by the central and local laboratories. Details are provided in Supplementary Table S2. These patients who were *TP53*-WT on local testing but *TP53*-mutant on central laboratory assessment were excluded from the response-evaluable cohort.

Dose Escalation and Toxicity

As shown in Figure 1, arm A began enrollment at 0.16 mg/kg, and arm B began enrollment once the third dose level in arm A (DL-3A) was completed. Enrollment proceeded in dose increments of 100% until grade ≥ 2 drug-related TEAEs were observed in DL-4A (fatigue) and in DL-3B (neutropenia); subsequent dose escalations in DL-5A and DL-4B continued with a modified Fibonacci sequence (i.e., 67%, 50%, 40%, and 33%) up to 4.4 mg/kg once-weekly in arm A and 2.7 mg/kg twice-weekly in arm B. Due to hypotension observed in patients during infusion at DL-7A, DL-7A-2 was introduced to evaluate a 2-hour infusion time with dexamethasone and fluids administered in cycles 1 and 2. All other patients received ALRN-6924 via a 1-hour infusion.

All 71 enrolled patients received at least one dose of ALRN-6924 and were included in the safety analysis population. All 71 patients experienced at least one TEAE. Common TEAEs (defined as $\geq 10\%$ occurrences) across both treatment arms are shown in Supplementary Table S3. These TEAEs were primarily grade 1 and 2 (60.6%), and the most frequent TEAEs regardless of relationship to study treatment included nausea (73.2%), fatigue (60.6%), vomiting (46.5%), anemia and headache (31.0% each), decreased appetite and constipation (29.6% each), and diarrhea (19.7%). In general, there were no marked differences in the incidence of TEAEs between arm A and arm B and no apparent dose-related trends. There were no fatal TEAEs.

Table 2 shows all observed grade ≥ 3 drug-related TEAEs. Overall, these occurred in 22.5% of patients (16/71). The rate of drug-related grade ≥ 3 TEAEs was similar in arms A and B. Only two patients experienced drug-related grade 4 TEAEs, one patient with neutropenia in each arm; no grade 5 TEAEs were observed.

Protocol-defined DLTs were experienced by five patients in treatment arm A. Dose escalation for this regimen proceeded to the 3.1 mg/kg dose level, wherein nine patients were treated and only one experienced a DLT (i.e., grade 3 fatigue that did not respond to supportive treatment within 48 hours). Dose escalation then continued to 4.4 mg/kg, where four DLTs were noted among the 11 patients across both 1- and 2-hour ALRN-6924 infusions, including grade 3 anemia (n = 1), grade 3 hypotension (n = 1), grade 4 neutropenia (n = 1), and grade 3 elevated alkaline phosphatase level (n = 1). The patient with a DLT of grade 3 fatigue recovered following dose delay within the seven days prior to the next clinical visit and continued treatment after dose reduction. The patient with grade 3 anemia continued treatment without dose reduction and without clinical symptoms or complications and recovered within 34 days. The patients experiencing DLTs of grade 3 hypotension and grade 4 neutropenia discontinued treatment and recovered within 5 and 7 days, respectively. The patient with a DLT of grade 3 elevated alkaline phosphatase level discontinued treatment and did not recover, and a subsequent liver biopsy revealed diffuse breast cancer metastases. Based on these DLTs, ALRN-6924 administered at 4.4 mg/kg once-weekly in arm A was considered to exceed the maximum tolerated dose (MTD) and was not further explored. The safety, PK, PD, and anti-tumor activity of ALRN-6924 at doses up to 3.1 mg/kg was considered favorable for further exploration as a single-agent in specific tumor types and in combination studies with other anti-cancer agents. While no DLTs were observed in arm B, and the efficacy profile in arm B was similar to that in arm A (*vide infra*), the twice-weekly regimen was considered less convenient than the once-weekly schedule and was not pursued.

A total of 11 serious adverse events (SAEs) were reported in seven patients in arm A and one patient in arm B. Of these serious adverse events, three in two patients were considered treatment-related. One patient had grade 3 hypotension and shortness of breath at the 3.1 mg/kg dose level in arm A, likely due to a drug-drug interaction. This patient presented with hypotension the day after ALRN-6924 dosing following self-administration of the anti-hypertensive agent telmisartan, a prohibited concomitant medication. Telmisartan is primarily cleared by hepatobiliary transporter OATP1B3, for which ALRN-6924 is an inhibitor.²⁷ Pharmacokinetic samples from this patient showed elevated plasma levels of telmisartan from the self-administered dose. The second patient had two events of grade 3 hypotension at the 4.4 mg/kg dose level in arm A, a dose level determined to be above the MTD. Both events occurred at the time of infusion and no apparent drug-drug interaction was identified. The second event resulted in discontinuation of study treatment and was considered a DLT as discussed above. To mitigate potential infusion-related hypotension as a safety concern, the clinical protocol was amended to specify that IV fluids (saline) or oral fluids (500mL – 1000 mL) should be administered at the end of the infusion.

Five patients (7.0%) discontinued treatment due to at least one drug-related TEAE, all in arm A. The TEAEs leading to treatment discontinuation were infusion-related reactions (n = 3), hypotension (n = 1), and neutropenia (n = 1).

The rates of dose reductions were 6/41 (14.6%) in arm A and 3/30 (10%) in arm B. In arm A, the dose of ALRN-6924 was reduced in response to mild to moderate fatigue, nausea, and vomiting in five patients across dose levels from 2.1 to 4.4 mg/kg, and in one patient with grade 2 chest pain at 2.1 mg/kg. In arm B, one patient with grade 3 diarrhea at the 0.8 mg/kg dose level was dose-reduced, as was one patient with

grade 3 nausea at 2.0 mg/kg and one patient with grade 1 fatigue and grade 1 nausea at 2.7 mg/kg. Notably, the observed toxicities were acute, with no evidence of cumulative hematologic or non-hematologic toxicities. Ophthalmic examination was not specified in the ALRN-6924 clinical trial, and no serious AEs related to eye disorders were reported.

Pharmacokinetic and Pharmacodynamic Studies

Noncompartmental pharmacokinetic parameters and fold-change from baseline in serum MIC-1 levels are shown in Table 3. Following a single IV infusion, ALRN-6924 achieved C_{\max} at the end of infusion, and the mean C_{\max} values ranged dose-proportionally from 3.4 to 96.4 $\mu\text{g/mL}$ over the dose range of 0.16 to 4.4 mg/kg (Figure 2A). The mean AUC across all collection time points (AUC_{all}) increased slightly more than dose-proportionally from 8.0 to 1200 $\mu\text{g}\cdot\text{hr/mL}$ over this same dose range, while the mean half-life also increased with increasing dose levels and ranged from 1.5 to 6.8 h (see Supplemental Information). The mean apparent clearance decreased with increasing dose and ranged from 3.70 to 23.5 mL/h/kg, whereas volume of distribution ranged from 25.7 to 51.1 mL/kg independent of dose level. Plasma pharmacokinetic results for individual patients on subsequent dosing days and subsequent cycles of therapy showed no accumulation of exposure, reproducible dose-to-dose exposure, and no indication of changes in exposure due to possible induction or inhibition of clearance mechanisms (data not shown). Noncompartmental pharmacokinetic parameters for seven patients with complete pharmacokinetic sample collection at the 3.1 mg/kg dose level are shown in Figure 2B. At the RP2D, ALRN-6924 exhibited a C_{\max} of 71.2 $\mu\text{g/mL}$, AUC_{all} of 705 $\mu\text{g}\cdot\text{hr/mL}$, and half-life of 5.4 hours, with a coefficient of variation of 20% and 26% for C_{\max} and AUC_{all} , respectively. No ALRN-6924-specific anti-drug antibodies were detected in any patient following administration of ALRN-6924.

Pharmacodynamic activity of ALRN-6924 was demonstrated by dose-related elevations of serum MIC-1, which is an established biomarker for activation of the p53 pathway (Figure 2C). A 10-fold increase in MIC-1 levels was observed by 8 hours after a single dose starting at 0.8 mg/kg, with a gradual decline to baseline after 24 hours at doses of 1.25 mg/kg and below, while doses of 2.1 mg/kg and above demonstrated a sustained elevation of MIC-1 up to 48 hours post-dose.

Anti-tumor Activity

The efficacy-evaluable population included patients who received at least one dose of ALRN-6924 at dose levels ≥ 0.8 mg/kg, had confirmed *TP53* wild-type tumors, and had undergone post-baseline radiological tumor assessment or exhibited clinical or objective progression as determined by the investigator. A total of 41 of the 71 enrolled patients were evaluable for response (a CONSORT diagram is shown in Supplementary Figure S1). The best change in target lesion size is shown in Figure 3A. Of the 41 evaluable patients, 24 patients (59%) demonstrated disease control by RECIST 1.1 or IWG 2014 criteria. Four patients achieved a response: two patients (one with PTCL and one with Merkel cell carcinoma) achieved a confirmed complete response (CR) and two patients (one with CRC and one with liposarcoma) demonstrated a confirmed partial response (PR). Twenty patients (49%) achieved stable disease (SD), with 55% of the patients with SD experiencing shrinkage of target lesions. The overall disease control rate was 59% (24/41), and among the 24 patients with disease control, the median duration of clinical benefit was 7.5 months at the time of data cutoff. A swimmer plot of treatment duration is shown in Figure 3B.

Overall, seven of 71 patients received ≥ 15 cycles of treatment, and six patients remained on treatment for over 1 year, including five patients who continued treatment beyond the data cutoff. A patient with PTCL achieved a durable CR at cycle 6 of the 2.1 mg/kg dose level in arm A, and at the time of data cutoff, the

patient had remained on treatment for 52 months. The patient with Merkel cell carcinoma showed a CR at the sixth cycle of treatment at the 2.7 mg/kg dose level in arm B, and the CR lasted for 6.5 months; this patient continued to receive clinical benefit and remained on treatment for 26 months. A patient with CRC who was treated at the 0.8 mg/kg dose level in arm B experienced continuous tumor shrinkage that met the criteria for PR at cycle 15 and remained on treatment for 16 months. A patient with liposarcoma achieved a durable PR at the 4.4 mg/kg dose level in arm A at cycle 8 and remained on treatment for 32 months. Two patients with thymoma achieved durable stable disease, one at the 2.1 mg/kg dose level in arm A for 57 months and another at the 2.7 mg/kg dose level in arm B for 17 months.

Association Between Molecular Alterations and Anti-tumor Activity

Genomic sequencing results from the Ion Torrent PGM platform (Knight Diagnostic Laboratories) were available for all four patients with objective responses. The patient with rectal cancer who experienced a PR had a KRAS G12D mutation and a subclonal PIK3CA P381S variant. The patient with Merkel cell cancer who had a CR had a variant of unknown significance in ALK (N1394H). The other two patients, one with liposarcoma and the other with PTCL, had no mutations in the 36 cancer-related genes sequenced.

We enrolled 10 *TP53*-WT patients with *MDM2* amplification as determined by central or local laboratory next-generation sequencing; of these, seven were in the efficacy-evaluable population (dose \geq 0.8 mg/kg), including four patients with liposarcoma and one patient each with bladder carcinoma, gastric adenocarcinoma, and breast cancer. Among these seven *MDM2*-amplified, efficacy-evaluable patients, five patients (71%) patients achieved disease control, including one with PR (liposarcoma) and four with SD as best overall response (Figure 3A).

Anti-tumor activity was compared to pretreatment tumor biopsy levels of the full-length MDMX gene transcript (MDMX_{-FL}) and a splice variant that skips exon 6 to encode a truncated isoform, MDMX_{-short}. Nucleic acid extracts derived from tumor tissue for next-generation sequencing of *TP53* were available in sufficient quantity for gene expression analysis for 28 of 41 efficacy-evaluable patients, including all four patients with CR or PR, and 13 with SD as their best response, and 11 with PD as their best response. As shown in Figure 2C, across the range of tumor types evaluated in this phase 1 study, a trend was observed in which patients with lower expression levels of MDMX_{-short} were more likely to achieve disease control (CR, PR, or SD as best overall response) than were patients with higher MDMX_{-short} levels; however, this association did not reach statistical significance.

Additional biomarker analyses showed no trend between ALRN-6924 anti-tumor activity and protein levels of p53, MDM2, or MDMX_{-FL} by either immunohistochemistry analysis of available formalin-fixed pretreatment biopsy samples or by gene expression levels of *TP53*, MDM2, or MDMX_{-FL} (data not shown). MDMX_{-short} protein levels were not evaluated by immunohistochemistry.

Discussion

This study is the first clinical trial of ALRN-6924, a stabilized, cell-permeating, α -helical stapled peptide, and is also the first clinical trial of a dual MDM2/MDMX inhibitor. Two single-agent dosing regimens were evaluated to assess safety and anti-tumor activity on a once-weekly or twice-weekly dosing schedule, with these treatment regimens including a 14-day (arm A) or 10-day (arm B) break between the last dose of one cycle and the first dose of the next, to allow recovery from potential toxicities. ALRN-6924 showed a good safety profile, with mild to moderate nausea, fatigue, and vomiting as the most common drug-related toxicities, and yielded disease control and objective responses in patients with a variety of tumor types.

Over the past decade, several MDM2 inhibitors have entered clinical trials, including RG7112 (RO5045337), idasanutlin (RG7388), AMG-232 (KRT-232), APG-115, CGM097, siremadlin (HDM201), milademetan (DS-3032b), MK-8242, and SAR405838.^{13,14,28-35} A striking finding in our study was the limited myelosuppressive effect of ALRN-6924, in contrast with clinical trial reports from small molecule MDM2 inhibitors (Supplementary Table S4). In reports from other MDM2 inhibitors, neutropenia and thrombocytopenia were often the dose limiting toxicities as detailed in a recent review by Konopleva et al.²⁸ MDM2 is involved in normal hematopoiesis, and treatment with MDM2 antagonists can lead to on-target hematopoietic defects.^{36,37} Of all 37 normal tissues reported in the Protein Atlas,^{38,39} MDMX expression is highest in bone marrow cells, which may contribute to the lower degree of bone marrow toxicity observed with a dual MDM2/MDMX inhibitor. We speculate that high MDMX levels may act as a pharmacokinetic “sink” to sequester ALRN-6924 in bone marrow cells and minimize its inhibition of MDM2, thereby minimizing MDM2-mediated ubiquitination and degradation of p53 in bone marrow cells. This concept remains a topic of continued research.⁴⁰

ALRN-6924 demonstrated favorable pharmacokinetic properties, with reproducible patient-to-patient values for key pharmacokinetic parameters as judged by the narrow coefficients of variation for C_{\max} and AUC_{all} , 20%, and 26%, respectively. This narrow range of variability in exposure contrasts with the inherent variability associated with uptake of oral drugs, allowing target therapeutic exposures to be more readily achieved with IV administration of ALRN-6924 without unexpected high exposure leading to toxicities seen with oral agents, in particular small molecule MDM2 inhibitors, which are oral.

Because ALRN-6924 activates p53, which is a transcription factor, the pharmacodynamic response to ALRN-6924 is moderated by the unique nature of its target. Serum levels of MIC-1, a protein under transcriptional control of p53, rapidly increased after ALRN-6924 dosing, demonstrating activation of the p53 pathway in tissues in response to the drug. MIC-1 levels were sustained for over 48 hours at the RP2D, well after the drug was mostly cleared from circulation, indicating a long-acting PD effect of p53 activation by ALRN-6924. This multi-day PD effect, considered in tandem with the disease control rate and objective responses observed on both once-weekly and twice-weekly dosing regimens, indicates that intermittent IV dosing of ALRN-6924 can produce satisfactory anti-tumor activity, and more frequent administration is not necessarily needed despite a plasma half-life of 5.4 hours at the RP2D.

The once-weekly dosing of ALRN-6924 at 3.1 mg/kg was chosen as the RP2D based on observed safety, tolerability, and anti-tumor activity. No DLTs were observed in arm B, and while the per-cycle drug exposure and favorable risk/benefit profile were similar for the two regimens at the highest tolerated doses tested, the once-weekly infusion schedule was considered more convenient by patients and investigators.

Encouraging single-agent activity, including durable CRs and PRs, was observed in a number of patients with different tumor types despite the heavily pretreated nature of this patient population. Furthermore, more than half of the evaluable patients achieved disease control. The durable CRs seen in Merkel cell carcinoma and PTCL highlight these diseases as potential therapeutic opportunities. The PR observed in the patient with colorectal cancer harboring *KRAS* mutation emphasizes that although *TP53* mutations are known to be enriched in metastatic CRC compared to primary tumors, over 40% of patients with CRC have *TP53*-WT tumors, so targeting MDM2/MDMX may hold promise.^{41,42} Notably, a previous study with SAR405838 and

pimasertib also showed some activity, with prolonged SD in CRC patients with a *KRAS* mutation and *TP53*-WT.⁴³

Liposarcoma has been considered a disease of interest for MDM2 inhibitors, as MDM2 amplifications have been reported in over 60% of liposarcomas.⁴⁴ Further, in dedifferentiated liposarcoma, MDM2 amplification and MDM2 overexpression was associated with shorter time to recurrence after surgical resection and reduced overall survival in patients receiving systemic therapy.⁴⁵ In the phase I trial reported here, we observed a partial response in one of five evaluable patients with liposarcoma and stable disease in the other four. Partial responses have also been reported in liposarcoma with other MDM2 inhibitors, including MK-8242 and milademetan (DS-3032B or RAIN-32),^{29,30} emphasizing that targeting MDM2 or MDM2/MDMX in liposarcoma alone or in combination therapy may be another therapeutic opportunity.

An intriguing correlation was observed between anti-tumor activity and pretreatment expression levels in patient tumors for an MDMX splice variant that skips exon 6 to encode a truncated isoform, MDMX_{-short}. High expression of MDMX_{-short} has been associated with faster progression and poorer survival in several cancers.⁴⁶ While the exact mechanism of this association remains controversial, one theory suggests that alternate splicing is a mechanism for posttranslational regulation of MDMX_{-FL} protein levels, such that the MDMX_{-short} splicing event leads to nonsense-mediated mRNA decay and a truncated protein that is also rapidly degraded, yielding lower levels of MDMX_{-FL} protein expression.⁴⁷ Therefore, tumor cells with low levels of MDMX_{-short} expression may have higher MDMX_{-FL} expression and greater dependence on MDMX for p53-dependent and p53-independent mechanisms for survival.⁴⁸ Analysis of the 28 efficacy-evaluable patients for whom a sufficient sample was available revealed that across the range of tumor types and doses evaluated in this phase 1 study, patients with lower expression levels of MDMX_{-short} were more likely to

achieve disease control (CR, PR, or SD as best overall response) than were patients with higher MDMX_{short} levels. While the number of patients tested in this assay was small and the results did not reach statistical significance, the trend suggests that MDMX inhibition by ALRN-6924 provides greater anti-tumor activity against tumors with lower MDMX_{short} levels. Alternative MDMX splicing is one of several mechanisms that can affect the function of p53, but with further study, this biomarker may be useful to select patients with a higher likelihood of response to ALRN-6924 therapy.

The disease control rate observed in this study suggests that p53 activation by ALRN-6924 may induce cell cycle arrest in *TP53*-WT tumor tissues, while the favorable tolerability profile, especially the virtual absence of thrombocytopenia and neutropenia that is otherwise common for MDM2 inhibitors, indicates that ALRN-6924 does not induce profound levels of apoptosis in healthy tissues such as bone marrow, even at the highest tested doses. This further suggests that besides its use as an anti-cancer drug, ALRN-6924 may be an ideal agent for treatment of normal, healthy *TP53*-WT tissues, such as bone marrow, when administered at lower doses more likely to induce cell cycle arrest, resulting in protection from the toxic effects of chemotherapy. This concept, known as cyclotherapy,⁴⁹ has been proposed for MDM2 inhibitors^{50,51} and was recently demonstrated in the clinic for a CDK4/6 inhibitor.⁵² Because approximately half of all cancers carry inactivating mutations in the *TP53* gene, which renders *TP53*-mutant cancer cells insensitive to the effects of ALRN-6924, prophylactic treatment with ALRN-6924 prior to chemotherapy may induce cell cycle arrest in normal tissues with wild-type *TP53* while leaving the rapidly proliferating *TP53*-mutant cancer cells susceptible to S- or M-phase poisons, such as topoisomerase inhibitors (which are most effective in S phase) or drugs targeting the mitotic spindle, such as taxanes (which are most effective during mitosis).⁵³ In conclusion, this study demonstrated the safety of first-in-class dual MDM2/MDMX inhibitor of ALRN-6924. ALRN-6924 yielded disease control and objective responses in patients with a variety of *TP53*-WT

tumors. The limited myelosuppression observed has provided rationale for ongoing clinical trials with ALRN-6924 as a chemoprotective drug for patients with *TP53*-mutant cancers.

Contributors

MNS, FMB, JRI, TMB, SG, GSF, GIS, KC, RMC, DSH, JSW, and MRP were responsible for patient enrollment, data collection, and data assembly. MNS, FMB, US, GN, VV, DAA, and MA were responsible for data analysis and interpretation. MNS, GN, DAA and FMB wrote the first draft of the report, and all authors were responsible for writing, editing, and approving the report.

Acknowledgments

We thank the research data managers, coordinators, and nurses, including Krystle Luna, Mohammad Ghalib, and Imran Chaudhary, for their contributions. We thank Stephanie Deming and Ashli Nguyen-Villarreal in the Research Medical Library at The University of Texas MD Anderson Cancer Center for editorial assistance, and Eric Smith for graphical assistance. This study was funded by Aileron Therapeutics.

References

1. Vousden KH, Lane DP. p53 in health and disease. *Nat Rev Mol Cell Biol* 2007; **8**(4): 275-83.
2. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. *Nature* 1989; **342**(6250): 705-8.
3. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. *Nature reviews Cancer* 2013; **13**(2): 83-96.
4. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS letters* 1997; **420**(1): 25-7.
5. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. *The EMBO journal* 1996; **15**(19): 5349-57.
6. Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. *Nature* 2018; **555**(7696): 321-7.

7. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. *Science* 1996; **274**(5289): 948-53.
8. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. *Proceedings of the National Academy of Sciences of the United States of America* 2003; **100**(21): 12009-14.
9. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. *Nature* 1995; **378**(6553): 203-6.
10. Parant JM, Reinke V, Mims B, Lozano G. Organization, expression, and localization of the murine mdmx gene and pseudogene. *Gene* 2001; **270**(1-2): 277-83.
11. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. *Science* 2004; **303**(5659): 844-8.
12. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. *Cancer research* 2006; **66**(6): 3169-76.
13. Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, et al. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2016; **22**(4): 868-76.
14. de Jonge M, de Weger VA, Dickson MA, Langenberg M, Le Cesne A, Wagner AJ, et al. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. *European journal of cancer* 2017; **76**: 144-51.
15. Ravandi F, Gojo I, Patnaik MM, Minden MD, Kantarjian H, Johnson-Levonas AO, et al. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). *Leukemia research* 2016; **48**: 92-100.
16. Iancu-Rubin C, Mosoyan G, Glenn K, Gordon RE, Nichols GL, Hoffman R. Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. *Experimental hematology* 2014; **42**(2): 137-45 e5.
17. Schafmeister CE, Po J, Verdine GL. An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides. *J Am Chem Soc* 2000; **122**(24): 5891-2.
18. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. *Journal of the American Chemical Society* 2007; **129**(9): 2456-7.
19. Verdine GL, Hilinski GJ. Stapled peptides for intracellular drug targets. *Methods Enzymol* 2012; **503**: 3-33.
20. Okamoto T, Zobel K, Fedorova A, Quan C, Yang H, Fairbrother WJ, et al. Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. *ACS Chem Biol* 2013; **8**(2): 297-302.
21. Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH, et al. Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. *Proceedings of the National Academy of Sciences of the United States of America* 2013; **110**(36): E3445-54.
22. Carvajal LA, Neria DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. *Science translational medicine* 2018; **10**(436).
23. Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. *Nature communications* 2018; **9**(1): 2024.
24. Penel N, Kramar A. What does a modified-Fibonacci dose-escalation actually correspond to? *BMC Med Res Methodol* 2012; **12**: 103.
25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *European journal of cancer* 2009; **45**(2): 228-47.
26. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol* 2014; **32**(27): 3059-68.
27. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. *Drug Metab Dispos* 2006; **34**(7): 1109-15.

28. Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, et al. MDM2 inhibition: an important step forward in cancer therapy. *Leukemia* 2020.
29. Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, et al. Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. *J Clin Oncol* 2017; **35**(12): 1304-11.
30. Bauer TM, Gounder MM, Weise AM, Schwartz GK, Carvajal RD, Kumar P, et al. A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). *Journal of Clinical Oncology* 2018; **36**(15_suppl): 11514-.
31. Siu LL, Italiano A, Miller WH, Blay J-Y, Gietema JA, Bang Y-J, et al. Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. *Journal of Clinical Oncology* 2014; **32**(15_suppl): 2535-.
32. Yee K, Martinelli G, Vey N, Dickinson MJ, Seiter K, Assouline S, et al. Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). *Blood* 2014; **124**(21): 116-.
33. Rasco DW, Lakhani NJ, Li Y, Men L, Wang H, Ji J, et al. A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors. *Journal of Clinical Oncology* 2019; **37**(15_suppl): 3126-.
34. Stein E, Chromik J, DeAngelo DJ, Chatterjee M, Noppeney R, Vos Fd, et al. Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advanced TP53 wt acute leukemias. *Cancer research* 2017; **77**(13 Supplement): CT152-CT.
35. Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA, et al. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. *Invest New Drugs* 2020; **38**(3): 831-43.
36. Mahfoudhi E, Lordier L, Marty C, Pan J, Roy A, Roy L, et al. P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. *Oncotarget* 2016; **7**(22): 31980-92.
37. Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. *J Hematol Oncol* 2017; **10**(1): 133.
38. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. *Science* 2015; **347**(6220): 1260419.
39. <http://www.proteinatlas.org>
40. Carvajal LA, Ren J-G, Guerlavais V, Steidl UG, Aivado M, Annis A. ALRN-6924, A Dual Inhibitor of MDMX And MDM2 That Causes Minimal Thrombocytopenia In Patients, Disrupts Different Stages Of Thrombopoiesis Compared To Mdm2-Only Inhibition European Hematology Association 24th Congress. Amsterdam; 2019.
41. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. *J Clin Oncol* 2012; **30**(24): 2956-62.
42. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012; **487**(7407): 330-7.
43. Hata AN, Rowley S, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Ji F, et al. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. *Oncogene* 2017; **36**(47): 6581-91.
44. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, et al. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. *JCO Precision Oncology* 2018; (2): 1-14.
45. Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, et al. Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. *Oncologist* 2019; **24**(7): 989-96.
46. Bardot B, Bouarich-Bourimi R, Leemput J, Lejour V, Hamon A, Plancke L, et al. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity. *Oncogene* 2015; **34**(22): 2943-8.
47. Valianatos G, Valcikova B, Growkova K, Verlande A, Mlcochova J, Radova L, et al. A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein. *PLoS One* 2017; **12**(10): e0185801.

48. Lenos K, Grawenda AM, Lodder K, Kuijjer ML, Teunisse AF, Repapi E, et al. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. *Cancer research* 2012; **72**(16): 4074-84.
49. Choong ML, Yang H, Lee MA, Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. *Cell Cycle* 2009; **8**(17): 2810-8.
50. Brown CJ, Quah ST, Jong J, Goh AM, Chiam PC, Khoo KH, et al. Stapled peptides with improved potency and specificity that activate p53. *ACS Chem Biol* 2013; **8**(3): 506-12.
51. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. *Cancer research* 2005; **65**(5): 1918-24.
52. Weiss JM, Csozsi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. *Ann Oncol* 2019; **30**(10): 1613-21.
53. Dobbstein M, Levine AJ. Mdm2: Open questions. *Cancer Sci* 2020.

Data sharing

Qualified researchers may request de-identified patient-level data by contacting Aileron Therapeutics (Cambridge, MA).

Table 1: Demographic characteristics of patients overall and in treatment arms A and B.

Characteristics	Arm A (n=41)	Arm B (n=30)	Total (n=71)
Median age, years (range)	62 (25-78)	58 (31-76)	61 (25-78)
Sex, n (%)			
Male	20 (48.8)	15 (50.0)	35 (49.3)
Female	21 (51.2)	15 (50.0)	36 (50.7)
Race, n (%)			
Caucasian	28 (68.3)	25 (83.3)	53 (74.6)
African American	9 (22.0)	4 (13.3)	13 (18.3)
Asian	1 (2.4)	0	1 (1.4)
Other	3 (7.3)	1 (3.3)	4 (5.6)
Ethnicity, n (%)			
Hispanic or Latino	4 (9.8)	1 (3.3)	5 (7.0)
Not Hispanic or Latino	34 (82.9)	26 (86.7)	60 (84.5)
Unknown	3 (7.3)	3 (10)	6 (8.5)
ECOG PS, n (%)			
0	13 (31.7)	9 (30.0)	22 (31.0)
1	28 (68.3)	21 (70.0)	49 (69.0)
Prior lines of treatment, n (%)			
1 or 2	9 (22.0)	14 (46.7)	23 (32.4)
3 or 4	11 (26.8)	6 (20.0)	17 (23.9)
≥5	21 (51.2)	10 (33.3)	31 (43.7)
Tumor <i>TP53</i> -WT, n (%)	34 (82.9)	30 (100)	64 (90.1)

ECOG PS, Eastern Cooperative Oncology Group performance status

Table 2: Drug-related grade ≥ 3 treatment-emergent adverse events

	Arm A n=41 n (%)	Arm B n=30 n (%)	Total n=71 n (%)
Patients with at least one grade ≥ 3 TEAE event	10 (24.4)	6 (20.0)	16 (22.5)
Adverse Event			
Fatigue	2 (4.9)	1 (3.3)	3 (4.2)
Anemia	1 (2.4)	1 (3.3)	2 (2.8)
Neutropenia	1 (2.4)	1 (3.3)	2 (2.8)
Nausea	1 (2.4)	1 (3.3)	2 (2.8)
Infusion-related reaction	2 (4.9)	0	2 (2.8)
Hyponatraemia	1 (2.4)	1 (3.3)	2 (2.8)
Hypotension	2 (4.9)	0	2 (2.8)
Diarrhea	0	1 (3.3)	1 (1.4)
Vomiting	0	1 (3.3)	1 (1.4)
Asthenia	1 (2.4)	0	1 (1.4)
Aspartate aminotransferase increased	1 (2.4)	0	1 (1.4)
Alkaline phosphatase increased	1 (2.4)	0	1 (1.4)
Hypoxia	1 (2.4)	0	1 (1.4)

TEAE, treatment-emergent adverse event.

Table 3. Noncompartmental pharmacokinetic parameters and fold-change from baseline in serum MIC-1 levels [mean (% CV)] for patients with complete sample collection following a single one-hour IV infusion on cycle 1 day 1 at select doses.


	0.16 mg/kg	0.32 mg/kg	0.53 mg/kg	0.64 mg/kg	1.25 mg/kg	2.1 mg/kg	3.1 mg/kg	4.4 mg/kg
N	5	3	5	4	2	6	7	8
AUC _{all} ($\mu\text{g}\cdot\text{h}/\text{mL}$)	8.02 (52.7)	17.8 (20.4)	42.8 (68.9)	55.6 (25.3)	164 (35.2)	434 (53.2)	705 (26.4)	1200 (14.5)
C _{max} ($\mu\text{g}/\text{mL}$)	3.37 (26.5)	5.56 (5.8)	10.1 (40.8)	13.4 (16.6)	27.7 (22.5)	45.2 (40.4)	71.2 (19.6)	96.4 (13.1)
t _{1/2} (h)	1.5 (64.4)	1.97 (54.1)	2.57 (49.7)	2.72 (52.9)	2.22 (6.9)	4.63 (40.5)	5.36 (38.6)	6.84 (25.6)
CL ($\text{mL}/\text{h}/\text{kg}$)	23.5 (43.1)	17.4 (30.7)	16.6 (56.3)	12.1 (25.5)	8.10 (35.1)	6.49 (63.1)	4.74 (40.5)	3.70 (15.4)
V _z (mL/kg)	42.2 (46.6)	44.3 (31.2)	50.8 (40.7)	51.1 (76.9)	25.7 (28.5)	41.8 (62.8)	33.8 (26.9)	36.8 (36.4)
MIC-1 at 8 hr	n/d	7.7 (100)	6.0 (28)	n/d	8.9 (14)	10.5 (77)	9.6 (73)	9.6 (39)
MIC-1 at 24 hr	2.9 (102)	1.7 (40)	3.1 (42)	4.8 (75)	16.3 (32)	21.6 (87)	19.9 (67)	26.3 (57)
MIC-1 at 48 hr	1.4 (51)	1.1 (12)	1.5 (38)	1.6 (35)	2.6 (31)	8.1 (91)	14.0 (79)	24.2 (59)


AUC_{all}, area under the curve for all measurable sampling times; CL, clearance; C_{max}, maximum concentration; CV, coefficient of variation; hr, hour(s); N, number; n/d = not determined; t_{1/2}, half-life; V_z, volume of distribution



Figure 1. Study schema. Patients in arm A received ALRN-6924 on days 1, 8, and 15 of a 28-day cycle, while those in arm B received ALRN-6924 on days 1, 4, 8, and 11 of a 21-day cycle.

Figure 2. Pharmacokinetics and pharmacodynamics, and association of anti-tumor activity with *MDM2* amplification and *MDMX*_{-short} splice variant expression. (A) Plasma levels of ALRN-6924 following a single one-hour IV infusion. For clarity, only dose levels in arm A are shown. (B) Mean increase from baseline in serum macrophage inhibitory cytokine 1 levels following a single dose of ALRN-6924. For clarity, only select dose levels are shown. (C) Expression levels of the *MDMX*_{-short} splice variant in pretreatment tumor biopsy specimens for 28/41 efficacy-evaluable patients versus best overall response. Line demarks median value. Two-tailed p value = 0.099 (n.s.).

Figure 3. (A) Best overall response for efficacy-evaluable patients treated with ALRN-6924. The graph shows best response per the Response Evaluation Criteria in Solid Tumors 1.1 (or Revised International Working Group Response Criteria 2014 for patients with lymphoma) in 39 of 41 efficacy-evaluable patients. Two efficacy-evaluable patients with non-radiological evidence of disease progression are not shown. Response-evaluable patients with *TP53*-WT tumors with *MDM2* amplification are designated with an asterisk (*). (B) Swimmer plot of treatment duration for 41 efficacy-evaluable patients in arms A and B







Clinical Cancer Research

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type *TP53*

Mansoor N Saleh, Manish R. Patel, Todd M. Bauer, et al.

Clin Cancer Res Published OnlineFirst July 22, 2021.

Updated version	Access the most recent version of this article at: doi: 10.1158/1078-0432.CCR-21-0715
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2021/07/23/1078-0432.CCR-21-0715.DC1
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2021/08/11/1078-0432.CCR-21-0715 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.